BrainXell was founded in 2015 by Prof. Su-Chun Zhang in conjunction with the Discovery to Product (D2P) program of University of Wisconsin- Madison and operates out of a new facility in University Research Park. The company is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. They provide a range of high-purity, iPSC-derived human neurons for research and development with a focus on drug discovery. From motor neurons to cortical sub-types, they can provide specific models for both disease and normal drug screening. BrainXell is dedicated to delivering the highest quality products from both their off-the-shelf neurons as well as any custom service projects, in addition to developing stem cell therapy for neurological injuries and diseases through collaboration with pharmaceutical and healthcare industry.
